{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:43:59Z","timestamp":1790516639597,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,3,25]],"date-time":"2016-03-25T00:00:00Z","timestamp":1458864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,3,25]],"date-time":"2016-03-25T00:00:00Z","timestamp":1458864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"DOI":"10.1038\/bcj.2016.21","type":"journal-article","created":{"date-parts":[[2016,3,25]],"date-time":"2016-03-25T14:22:08Z","timestamp":1458915728000},"page":"e408-e408","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma"],"prefix":"10.1038","volume":"6","author":[{"given":"L","family":"Ratner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Rauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Abel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Noy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S K","family":"Barta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J C","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Ambinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H H","family":"Baydoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,25]]},"reference":[{"key":"BFbcj201621_CR1","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1182\/blood-2015-03-632489","volume":"126","author":"H Katsuya","year":"2015","unstructured":"Katsuya H, Ishitsuka K, Utsunomiya A, Hanada S, Eto T, Moriuchi Y et al. Treatment and survival among 1594 patients with ATL. Blood 2015; 126: 2570\u20132577.","journal-title":"Blood"},{"key":"BFbcj201621_CR2","doi-asserted-by":"publisher","first-page":"e4420","DOI":"10.1371\/journal.pone.0004420","volume":"4","author":"L Ratner","year":"2009","unstructured":"Ratner L, Harrington W, Feng X, Grant C, Jacobson S, Noy A et al. Human T cell leukemia virus reactivation with progression of adult T-cell leukemia-lymphoma. AIDS Malignancy Consortium. PLoS One 2009; 4: e4420.","journal-title":"PLoS One"},{"key":"BFbcj201621_CR3","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1128\/AAC.01413-10","volume":"55","author":"ME Seegulam","year":"2011","unstructured":"Seegulam ME, Ratner L . Integrase inhibitors effective against human T-cell leukemia virus type 1. Antimicrob Agents Chemother 2011; 55: 2011\u20132017.","journal-title":"Antimicrob Agents Chemother"},{"key":"BFbcj201621_CR4","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s13365-014-0249-3","volume":"20","author":"GS Brunetto","year":"2014","unstructured":"Brunetto GS, Massoud R, Leibovitch EC, Caruso B, Johnson K, Ohayon J et al. Digital droplet PCR (ddPCR) for the precise quantification of human T-lymphotropic virus 1 proviral loads in peripheral blood and cerebrospinal fluid of HAM\/TSP patients and identification of viral mutations. J Neurovirol 2014; 20: 341\u2013351.","journal-title":"J Neurovirol"},{"key":"BFbcj201621_CR5","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/bjh.13338","volume":"169","author":"T Ishida","year":"2015","unstructured":"Ishida T, Jo T, Takemoto S, Suzushima H, Uozumi K, Yamamoto K et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol 2015; 169: 672\u2013682.","journal-title":"Br J Haematol"},{"key":"BFbcj201621_CR6","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","volume":"25","author":"K Tsukasaki","year":"2007","unstructured":"Tsukasaki K, Utsonomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 2007; 25: 5458\u20135864.","journal-title":"J Clin Oncol"},{"key":"BFbcj201621_CR7","doi-asserted-by":"publisher","first-page":"e2418","DOI":"10.1371\/journal.pntd.0002418","volume":"26","author":"O Cassar","year":"2013","unstructured":"Cassar O, Einsiedel L, Afonso PV, Gessain A . Human T-cell lymphotropic virus type 1 subtype C molecular variants among indigenous Australians: new insights into the molecular epidemiology of HTLV-1 in Australo-Melanesia. PLoS Negl Trop Dis 2013; 26: e2418.","journal-title":"PLoS Negl Trop Dis"},{"key":"BFbcj201621_CR8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ccr.2011.12.015","volume":"21","author":"M Yamagishi","year":"2012","unstructured":"Yamagishi M, Nakano K, Miyake A, Yamochi T, Kagami Y, Tsutsumi A et al. Polycomb-mediated loss of miR-31 activated NIK-dependent NF-kB pathway in adult T cell leukemia and other cancers. Cancer Cell 2012; 21: 121\u2013136.","journal-title":"Cancer Cell"},{"key":"BFbcj201621_CR9","doi-asserted-by":"publisher","first-page":"5896","DOI":"10.1182\/blood-2008-09-181024","volume":"113","author":"T Krejsgaard","year":"2009","unstructured":"Krejsgaard T, CSV-K CS, Woetmann A, Kneitz H, Eriksen KW, Lovato P et al. Ectopic expression of B-lymphoid kinase in cutaneous T-cell lymphoma. Blood 2009; 113: 5896\u20135904.","journal-title":"Blood"},{"key":"BFbcj201621_CR10","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1038\/leu.2014.192","volume":"28","author":"DL Petersen","year":"2015","unstructured":"Petersen DL, Krejsgaard T, Berthelsen J, Fredholm S, Willerslev-Olsen A, Sibbesen NA et al. B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL). Leukemia 2015; 28: 2109\u20132112.","journal-title":"Leukemia"},{"key":"BFbcj201621_CR11","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4049\/jimmunol.161.1.209","volume":"161","author":"LR Soares","year":"1998","unstructured":"Soares LR, Tsavaler L, Rivas A, Engleman EG . V7 (CD101) ligation inhibits TCR\/CD3-induced IL-2 production by blocking Ca2+ flux and nuclear factor of activated T cell nuclear translocation. J Immunol 1998; 161: 209\u2013217.","journal-title":"J Immunol"},{"key":"BFbcj201621_CR12","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/ng.3415","volume":"47","author":"K Kataoka","year":"2015","unstructured":"Kataoka K, Nagata Y, Kitanaka A, Shiraishi Y, Shimamura T, Yasunaga J et al. Integrated molecular analysis of adult T-cell leukemia\/lymphoma. Nat Genet 2015; 47: 1304\u20131315.","journal-title":"Nat Genet"},{"key":"BFbcj201621_CR13","doi-asserted-by":"publisher","first-page":"9220","DOI":"10.1073\/pnas.0507809103","volume":"103","author":"L Bernal-Mizrachi","year":"2006","unstructured":"Bernal-Mizrachi L, Lovly CM, Ratner L . The role of nuclear factor kB-1 and -2-mediated resistance to apoptosis in lymphomas. Proc Natl Acad Sci USA 2006; 103: 9220\u20139225.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFbcj201621_CR14","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/cas.12617","volume":"106","author":"A Utsunomiya","year":"2015","unstructured":"Utsunomiya A, Choi I, Chihara D, Seto M . Recent advances in the treatment of adult T-cell leukemia-lymphomas. Cancer Sci 2015; 106: 344\u2013351.","journal-title":"Cancer Sci"},{"key":"BFbcj201621_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40425-015-0079-8","volume":"3","author":"J Kline","year":"2015","unstructured":"Kline J, Bishop MR . Update on checkpoint blockade therapy for lymphoma. J Immunother Cancer 2015; 3: 33.","journal-title":"J Immunother Cancer"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj201621.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201621","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201621.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T09:05:39Z","timestamp":1672823139000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj201621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,25]]},"references-count":15,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,3]]}},"alternative-id":["BFbcj201621"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2016.21","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,25]]},"assertion":[{"value":"25 March 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}